CTI BioPharma Corp – Strategy, SWOT and Corporate Finance Report

CTI BioPharma Corp – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360Ëš view of the company.

CTI BioPharma Corp (CTI BioPharma) is a biopharmaceutical company, which acquires, develops and commercializes targeted therapies for a range of blood-related cancers. The company’s lead product, Pixuvri (pixantrone) is an aza-anthracenedione used for the treatment of multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) in adults. Its pipeline portfolio consists of Pacritinib for the treatment of myelofibrosis for all platelet counts, relapsed acute myeloid leukemia (AML), other hematological and solid tumor indications; and Tosedostat for AML and myelodysplastic syndrome. The company has subsidiaries in the UK and the US. CTI BioPharma is headquartered in Seattle, Washington, the US.

Scope

Detailed information on CTI BioPharma Corp required for business and competitor intelligence needs

A study of the major internal and external factors affecting CTI BioPharma Corp in the form of a SWOT analysis

An in-depth view of the business model of CTI BioPharma Corp including a breakdown and examination of key business segments

News about CTI BioPharma Corp, such as business expansion, restructuring, and contract wins

Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

Gain understanding of CTI BioPharma Corp and the factors that influence its strategies.

Track strategic initiatives of the company and latest corporate news and actions.

Assess CTI BioPharma Corp as a prospective partner, vendor or supplier.

Support sales activities by understanding your customers' businesses better.

Stay up to date on CTI BioPharma Corps business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Clovis Oncology Inc

Geron Corp

Celgene Corp

Array BioPharma Inc

sanofi-aventis US LLC

Johnson & Johnson

Incyte Corp

Ariad Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

CTI BioPharma Corp - Key Facts

CTI BioPharma Corp - Key Employees

CTI BioPharma Corp - Key Employee Biographies

CTI BioPharma Corp - Major Products and Services

CTI BioPharma Corp - History

CTI BioPharma Corp - Company Statement

CTI BioPharma Corp - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 Company Analysis

Company Overview

CTI BioPharma Corp - Business Description

CTI BioPharma Corp - Corporate Strategy

CTI BioPharma Corp - SWOT Analysis

SWOT Analysis - Overview

CTI BioPharma Corp - Strengths

CTI BioPharma Corp - Weaknesses

CTI BioPharma Corp - Opportunities

CTI BioPharma Corp - Threats

CTI BioPharma Corp - Key Competitors

Section 3 Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 Company’s Lifesciences Financial Deals and Alliances

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

CTI BioPharma Corp, Recent Deals Summary

Section 5 Company’s Recent Developments

May 02, 2019: CTI BioPharma reports first quarter 2019 financial results

Mar 13, 2019: CTI BioPharma reports fourth quarter and full year 2018 financial results and recent highlights

Dec 13, 2018: CTI BioPharma Announces Restructuring Plan

Nov 01, 2018: CTI BioPharma reports third quarter 2018 financial results

Aug 02, 2018: CTI BioPharma reports second quarter 2018 financial results

May 03, 2018: CTI BioPharma Reports First Quarter 2018 Financial Results

Mar 07, 2018: CTI BioPharma Reports Fourth Quarter and Full Year 2017 Financial Results

Jan 25, 2018: CTI BioPharma Provides Corporate and European Regulatory Update

Section 6 Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List of Tables

List of Tables

CTI BioPharma Corp, Key Facts

CTI BioPharma Corp, Key Employees

CTI BioPharma Corp, Key Employee Biographies

CTI BioPharma Corp, Major Products and Services

CTI BioPharma Corp, History

CTI BioPharma Corp, Subsidiaries

CTI BioPharma Corp, Key Competitors

CTI BioPharma Corp, Ratios based on current share price

CTI BioPharma Corp, Annual Ratios

CTI BioPharma Corp, Annual Ratios (Cont…1)

CTI BioPharma Corp, Interim Ratios

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

CTI BioPharma Corp, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

CTI BioPharma Corp, Performance Chart (2014 – 2018)

CTI BioPharma Corp, Ratio Charts

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@marketline.com
+44 (0) 161 359 5817

Saved reports